Providers

Patients with obstructive sleep apnea (OSA) exhibited similarly improved insomnia and quality-of-life outcomes when administered hypoglossal nerve stimulation (HNS) vs standard-of-care positive airway pressure (PAP) therapy.

An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.

Two-third of those who receive a chronic lymphocytic leukemia (CLL) diagnosis are age 65 or older, so the ease with which drugs are covered in Medicare has an outsized role in patient access to care.

Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Two doses of the Pfizer vaccine may only have 22.5% efficacy against the Omicron variant; as of 2018, less than 16% of orthopedic specialists are people of color; a mask mandate for stores and indoor spaces in New York state went into effect.

Zanubrutinib produced prolonged progression-free survival (PFS) compared with a combination of bendamustine and rituximab among treatment-naïve patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL).

Investigators discuss the humoral response to enzyme-replacement therapy in their review of the clinical picture and diagnostic confirmation of Fabry disease.

Findings about the willingness of primary care providers to prescribe artificial pancreas systems have positive implications for increasing access to and reducing disparities around this technology by alleviating the need to see a specialist.

Posters review how a patient’s neighborhood impacts access to the liver transplant waitlist and how Medicaid expansion improved waitlist mortality.

High-flow nasal therapy overcomes some of the barriers associated with noninvasive ventilation, making the novel support beneficial for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD).

This new review examined oral health outcomes in children with growth hormone deficiency (GHD) following a search of the published literature from January 2000 through May 2021.

Guidelines recommend patients with nonalcoholic fatty liver disease (NAFLD) who are obese achieve 5% to 10% weight loss to prevent NAFLD progression.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, provides an overview of the emerging data at ASH 2021 on CAR T-cell therapy as a second- and first-line treatment.

This article describes the Philadelphia Medicaid Opioid Prescribing Initiative that was launched by a multidisciplinary team and mailed local Medicaid providers individualized prescribing report cards.

Findings presented today during EuroEcho 2021 demonstrate a potential link between persistent dyspnea following recovery from COVID-19 infection and subclinical cardiac dysfunction.

Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.

A high comorbidity burden, including psychiatric, autoimmune, and systemic conditions, was found in US adult ambulatory populations with atopic dermatitis.

Rates of sacubitril/valsartan diffusion have been slow and there has been significant geographic variation, highlighting the importance of local prescribing patterns in early drug diffusion.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, addresses major unmet needs in Fabry disease, ranging from uncontrolled pain to irreversible damage prior to treatment initiation.

Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).

This new study from Finland highlights both the potential for severe psychiatric disturbances among women with polycystic ovary syndrome (PCOS) and lack of extensive knowledge of the toll of psychoses among this group.

More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.

This commentary describes 4 dimensions of trust that have been illuminated by contributions from leading health care organizations to the ABIM Foundation’s Trust Practices Network.

The social, structural, and economic drivers of HIV are not so different from COVID-19. Still, those who have witnessed the ravages of HIV have been in a 40-year holding pattern when it comes to a vaccine, according to experts from the Rutgers School of Public Health.

A mobile app was shown to be feasible in identifying risk of obstructive sleep apnea and associated symptoms, as well as promoting management recommendations among an outpatient cohort.

Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.

President Joe Biden will provide an update today on his administration’s response to the Omicron COVID-19 variant; marked rise in lung transplants for patients with COVID-19 sparks ethical questions; an independent panel of experts will advise FDA tomorrow on the use of Merck’s COVID-19 antiviral pill.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, details various known and understudied health-related quality-of-life factors in patients with Fabry disease.